secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001558370-23-012028
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Coherus appoints Michael Ryan to board of directors
---------------------------------------------------

- Michael Ryan appointed to Coherus board effective July 18, 2023; fills Class III vacancy until 2026 annual meeting.
- Ryan has 40 years in biopharma; most recently SVP at Bristol-Myers Squibb and earlier VP at Amgen.
- Compensation: annual cash retainer of $50,000; initial option for 54,000 shares vesting monthly over 3 years.
- Also founder/CEO of Koios Enterprises, an executive consulting firm focusing on patient access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023012028/0001558370-23-012028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023012028/chrs-20230718x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-012028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer